Autres langues BioInvent International AB

Actions

BINV

SE0015244520

Marché Fermé - Nasdaq Stockholm Autres places de cotation 12:59:33 30/04/2024			Varia. 5j.	Varia. 1 janv.
26 ^SEK	+2,77%		+11,59%	+37,13%

30/04	BioInvent annonce l'évaluation de la technologie d'Attana	CI
24/04	BioInvent International AB (publ) annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

BioInvent evaluating Attana Technology	30/04
BioInvent Announces Evaluating Attana Technology	30/04
BioStock: BioInvent selected to present at ASCO in Chicago	29/04
BioInvent International AB, Interim report January-March 2024	25/04
BioInvent Q1 2024 - Approaching Catalysts	25/04
BioInvent to Present Clinical Data from its two leading assets at ASCO 2024	24/04
BioInvent International AB: Interim report January-March 2024	24/04
BioInvent International AB Reports Earnings Results for the First Quarter Ended March 31, 2024	24/04
BioInvent International AB publishes Annual Report 2023	04/04
BioStock: BioInvent deepens collaboration with MSD	04/04
BioInvent announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company s second anti-TNFR2 antibody in combination with KEYTRUDA	03/04
BioInvent, Merck & Co. Unit Sign Clinical Trial, Supply Deal for Tumor Treatment as Add-On Therapy for Keytruda	03/04
BioInvent International : announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company's second anti-TNFR2 antibody in combination with KEYTRUDA® (pembrolizumab)	02/04
BioInvent announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company’s second anti-TNFR2 antibody in combination with KEYTRUDA® (pembrolizumab)	02/04
Notice to Annual General Meeting in BioInvent International AB	27/03
BioStock: BioInvent's CEO comments on the study success in China	11/03
BioInvent International, CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed, Refractory Indolent Non-Hodgkin's Lymphoma In China	06/03
BioInvent International: CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China	05/03
BioInvent International: CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma In China	05/03
BioInvent International AB Year-end report January 1, December 31, 2023	23/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues BioInvent International AB

Actions

BINV

SE0015244520

Autres langues

Filtres